Resmed (RMD) Receivables - Other (2018 - 2026)

Resmed has reported Receivables - Other for 9 years, with the latest figure at $47.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 8.77% year-over-year to $47.1 million; the trailing twelve-month figure through Mar 2026 stood at $47.1 million (down 8.77% YoY), and the FY2025 full-year result was $51.2 million, up 34.03% from the prior year.
• Receivables - Other for Q1 2026 stood at $47.1 million, down from $61.4 million in the prior quarter.
• The five-year high for Receivables - Other was $61.4 million in Q4 2025, with the low at $23.1 million in Q4 2022.
• Historically, Receivables - Other has averaged $38.4 million across 5 years, with a median of $37.9 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Other jumped 135.86% — and 2026, when it declined 8.77%.
• Resmed's Receivables - Other stood at $23.1 million in 2022, then jumped by 49.62% to $34.6 million in 2023, then soared by 35.98% to $47.0 million in 2024, then soared by 30.61% to $61.4 million in 2025, then slipped by 23.29% to $47.1 million in 2026.
• The last three Receivables - Other figures came in at $47.1 million (Q1 2026), $61.4 million (Q4 2025), and $51.1 million (Q3 2025), per Business Quant data.